News | Cardiac Imaging | October 11, 2022

Identifying Patients with Sarcoidosis at Risk for Bad Cardiac Outcomes

Researchers from the University of Minnesota Medical School found that patients with certain features on magnetic resonance imaging (MRI) of the heart are at much higher risk for cardiac sarcoidosis-related adverse outcomes.

Chetan Shenoy, MBBS, MS


October 11, 2022 — Researchers from the University of Minnesota Medical School found that patients with certain features on magnetic resonance imaging (MRI) of the heart are at much higher risk for cardiac sarcoidosis-related adverse outcomes. These patients may benefit from an implantable cardioverter defibrillator. Meanwhile, other features identified patients at very low risk who might not benefit from the device. These findings were published recently in JAMA Cardiology

Cardiac sarcoidosis is a rare inflammatory heart disease that can result in rhythm disturbances and heart failure. Sarcoidosis is estimated to affect approximately 200,000 Americans.  

“Late gadolinium enhancement on cardiovascular magnetic resonance imaging is often used to diagnose cardiac sarcoidosis. Our research shows that not all patients with late gadolinium enhancement on cardiac MRI  have the same risk of adverse outcomes, particularly ventricular arrhythmias,” said Chetan Shenoy, MBBS, MS, an associate professor of medicine at the University of Minnesota Medical School and the lead author of the study. “We believe our findings will help optimize the clinical care of patients with suspected cardiac sarcoidosis, and consequently, lead to better outcomes.” 

In this largest study yet of suspected cardiac sarcoidosis investigated by cardiac MRI, the researchers studied 504 patients. The MRI features were based on the research team’s previously published study that described features of cardiac damage in the hearts of patients with cardiac sarcoidosis who had suddenly died or needed heart transplantation. 

Researchers note that these findings should be replicated in other, more diverse, cohorts. Whether clinical management guided by these cardiac MRI features improves outcomes in patients with suspected cardiac sarcoidosis should be prospectively tested in a randomized trial. 

For more information: www.med.umn.edu 

Related Cardiac Sarcoidosis Content: 

VIDEO: Utilization of PET For Evaluation of Cardiac Sarcoidosis 

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis 

New PET-CT Scan Improves Detection in Rare Cardiac Condition 

25 Most Impactful Nuclear Cardiology Articles 

Recent Advances in Cardiac Nuclear Imaging Technology 


Related Content

Feature | Heart Failure | Kyle Hardner

Editor's Note: This is Part Three of a three-part series highlighting several of the presentations from the American ...

Home May 13, 2026
Home
News | Heart Failure

May 10, 2026 — Results from the first randomized trial evaluating microRNA inhibition in heart failure were presented ...

Home May 11, 2026
Home
Feature | Heart Failure | Kyle Hardner

Could a link between the heart, brain and immune system help reduce the occurrence of heart attacks and lessen the ...

Home May 04, 2026
Home
News | Heart Failure

April 21, 2026 — Nuwellis, Inc. has announced a software update to its Aquadex SmartFlow ultrafiltration platform. The ...

Home April 23, 2026
Home
News | Heart Failure

March 28, 2026 — Amgen announced today that Repatha (evolocumab), when added to statins or other low-density lipoprotein ...

Home April 06, 2026
Home
News | Heart Failure

March 24, 2026 — New research shows that small improvements to sleep, diet quality and physical activity, made in ...

Home March 25, 2026
Home
News | Heart Failure

March 16, 2026 — Cytokinetics has announced four presentations related to Myqorzo (aficamten) at the American College of ...

Home March 16, 2026
Home
Feature | Heart Failure | Rohit Sood, MD, PhD

Cardiovascular disease (CVD) is a serious global health burden that encompasses a broad group of diseases that affect ...

Home February 12, 2026
Home
News | Heart Failure

Feb. 3, 2026 — Bristol Myers Squibb has launched "Change the Target. Change What’s Possible," an educational campaign ...

Home February 03, 2026
Home
News | Heart Failure

Jan. 27, 2026 — A new national study reveals a stark disconnect between Americans’ desire for preventive cardiac ...

Home January 27, 2026
Home
Subscribe Now